Cramer’s Exciting Revelation: Vertex Unveils Revolutionary Drug with Potential to Tackle the World’s Biggest Market

In a recent episode of “Squawk on the Street,” Jim Cramer from CNBC recommended that investors pay attention to Vertex Pharmaceuticals (VRTX). This biotechnology company is currently developing a non-opioid drug to treat acute pain.

Cramer stated, “The biggest challenge in the pharmacy industry is finding ways to alleviate pain without relying on opioids. Vertex is addressing this issue with their plan.”

Vertex, primarily known for its cystic fibrosis treatment Trikafta, is currently conducting late-stage trials for its pain drug, VX-548. The company aims to develop a new category of prescription medications that effectively relieve pain while mitigating the addictive potential associated with opioids.

Cramer expressed optimism about Vertex’s potential, stating, “If they succeed, it could be the largest market opportunity in the world.” He also mentioned that the results of the late-stage study for VX-548 are expected to be released within the next year.

Leerink Partners analysts highlighted the significant potential of VX-548 in a note to clients. They believe that the investment community is underestimating its impact. The firm, which rates Vertex shares as a buy, drew parallels between the current pain market and the obesity market a couple of years ago.

Cramer’s Charitable Trust, the portfolio used by the CNBC Investing Club, holds shares of Eli Lilly (LLY) in its pharmaceutical industry portfolio. The trust is invested in Eli Lilly due in part to the potential of their drug Mounjaro. Although currently approved for treating type-2 diabetes, Lilly expects Mounjaro’s approved uses to expand to include obesity by the end of the year. Cramer has even mentioned that Mounjaro could become the best-selling drug ever.